Research on lung cancer detection and treatment. Covers microbial predictors of immunotherapy, MRI detection, microplastics, and RAS-mutant drugs.
Researchers at the University of Florida have discovered a small compound produced by gut bacteria that doubles the response to lung cancer immunotherapy treatment in mice. The findings could lead to a new combination therapy that boosts patient responsiveness by 50% without adding invasive treatments.
A new blood test has been developed to predict which patients with lung cancer will benefit from the newly approved immunotherapy drug tarlatamab. The test, based on circulating tumor cells, correctly identified 85% of patients who responded to the drug and 100% of those who did not.
A new approach to treating KRAS-mutated lung adenocarcinomas has been identified, using a combination of ERBB inhibitors and Aurora kinase inhibitors. This therapy shows significant effectiveness against existing treatments, offering hope for patients with limited options.
The American Cancer Society's new 'Cancer Statistics, 2026' report reveals a historic milestone: US cancer survivorship has reached a record 70%, driven by major gains in cancers once considered difficult to treat. However, the report also highlights persistent disparities, concerning increases in cancer among women and younger adults.
Researchers at MD Anderson have made significant advancements in cancer treatment, demonstrating the effectiveness of immunotherapy before and after surgery in improving lung cancer patient outcomes. Additionally, a new study shows promise in using CAR T cell therapy to treat large B-cell lymphoma, reducing relapse rates.
A new study suggests that durvalumab may offer a promising treatment option for limited-stage small cell lung cancer patients, extending overall and progression-free survival. However, the therapy's high cost poses significant challenges to sustainability and access in the real-world setting.
A study published in Molecular Oncology developed a liquid biopsy panel that can detect specific gene mutations in lung cancer patients, offering a potential solution for early detection and guiding patient treatment. The test showed promising results, detecting mutations in 65.6% of samples, including those in frozen samples without s...
A new nanodrug called Nano-273 could offer improved survival for patients with pancreatic and lung cancers by activating the immune system and blocking tumor growth. The drug, developed by University of Houston researcher Wei Gao, has shown promising results in early studies.
A study found that high PD-L1 levels are associated with increased risk of lymph node metastasis and poorer recurrence-free survival rates in patients with pulmonary adenocarcinoma. This suggests that PD-L1 expression may serve as a potential indicator for early postoperative recurrence.
Dr Aldona Mzyk's project uses quantum sensors to track how immune cells interact with tumours, enabling the development of improved patient-tailored cancer therapies and earlier diagnosis tools. The research aims to overcome current cancer immunotherapies' failure in solid tumours by controlling metabolic changes.
Researchers have identified two proteins that allow cancer cells to evade destruction by brain immune cells, known as microglia. By removing these proteins, microglia play a key role in eliminating cancer cells during the early stage of their arrival in the brain.
A NIH-led study identified key factors driving tumor evolution and influence outcomes in lung cancer, revealing a previously unknown origin of aggressive tumors associated with the ID2 mutational signature linked to LINE-1 reactivation. Major driver gene mutations also influenced tumor evolutionary trajectories.
Researchers found that patients who received immunochemotherapy before 3:00 pm experienced significantly longer progression-free survival and overall survival compared to those treated later. Earlier administration of immunotherapy was also associated with lower risks of cancer progression and death.
A special issue of the Journal of the American College of Radiology highlights the transformation of lung cancer from a feared and stigmatized disease to one that is increasingly understood as chronic and treatable. Advances in screening, therapeutics, and survivorship have improved outcomes for patients.
Mayo Clinic researchers have found several previously unknown genetic and cellular processes that occur in lung adenocarcinoma tumors responding well to immunotherapy. The study identified markers that may predict a positive response to immunotherapy, including the presence of senescent tumor cells and loss of the PRKCI gene.
A population-based cohort study found that individuals following high-glycemic index diets had a 13% higher chance of developing lung cancer compared to those on low-GI diets. In contrast, those consuming high-glycemic load diets experienced a 28% lower risk of lung cancer.
A recent study led by Dr. Leah Backhus found that lung cancer patients often receive inadequate posttreatment surveillance, which can lead to a substantial gap in care. The study estimated the true surveillance rates and predictors of guideline-concordant care in patients with early-stage non-small cell lung cancer.
Current USPSTF guidelines exclude two-thirds of patients from age-based screening, disproportionately affecting women and never-smokers. Age-based screening has been shown to improve detection and demonstrated superior cost-effectiveness compared to existing programs.
Lung cancer screening has the potential to prevent 3 times more deaths and gain 3 times more life-years than current levels. Increasing awareness and accessibility of lung cancer screening could lead to wider adoption.
Researchers have shown that disabling the NRF2 gene with CRISPR technology can restore drug sensitivity and slow tumor growth in lung cancer. The approach, which targets a master switch for resistance, has potential across multiple tumor types.
Researchers at The University of Osaka have developed a novel Balloon-Assisted Bronchoscope Delivery (BDBD) technique, enabling safe access to small, early-stage lung cancers hidden in the peripheral lung fields. This innovation promises to revolutionize both early diagnosis and minimally invasive treatment.
The new clinical cancer research center will support lung and genitourinary cancers, serving as a central hub for seven VA medical centers. The grant aims to improve access to precision oncology trials and patient care for veterans diagnosed at later stages.
This pilot study evaluated the effectiveness of improved laser ablation with saline injection in treating early-stage lung adenocarcinoma. The modified system significantly expanded ablation zones, achieving a 100% complete ablation rate in six patients. The treatment was safe and effective, with no major complications reported.
Researchers found that Biaxially rotational dynamic radiation therapy (BROAD-RT) significantly reduced radiation doses to lungs, heart, and oesophagus compared to volumetric modulated arc therapy (VMAT). However, it resulted in greater low-dose lung exposure.
Researchers at Arizona State University discovered that SerpinB3 plays a natural role in the body's wound-healing process, helping skin recover after damage. The protein helps activate keratinocytes to rebuild tissue and improve skin strength.
Researchers at University of Texas M. D. Anderson Cancer Center discover that inflammation is responsible for driving the earliest stages of lung cancer, identifying potential targets for early intervention and suggesting a promising approach to intercepting lung cancer development.
Researchers discovered that blocking a specific protein called ferroptosis suppressor protein 1 (FSP1) reduces tumor growth by up to 80% in mice with lung adenocarcinoma. This study provides hope for developing novel clinical therapies for cancer patients.
A UT Dallas team developed an electrochemical biosensor that accurately identifies eight volatile organic compounds linked to thoracic cancers. AI analysis enhances the accuracy of breath samples, showing promise for early lung cancer detection and improved patient outcomes.
Scientists at Moffitt Cancer Center identify distinct approaches to combat drug resistance in non-small cell lung cancer, targeting RAS and CDK12/13 pathways. Combining therapies delays or prevents resistance, extending treatment response.
Patients with advanced lung and skin cancer who received a COVID-19 mRNA vaccine within 100 days of starting immunotherapy drugs lived significantly longer. The vaccine was associated with a near doubling of median survival, from 20.6 months to 37.3 months in lung cancer patients.
A direct-to-patient digital health intervention increased lung cancer screening rates compared to enhanced usual care. The study's findings suggest that such interventions could improve lung cancer screening across diverse populations and healthcare settings.
A new digital health program has been found to significantly increase lung cancer screening rates among people at high risk. The study, which tested a direct-to-patient program, showed that 24.5% of participants completed a screening CT scan within 16 weeks, compared to 17% in the usual care group.
UCLA investigators unveil decade-long survival data for immunotherapy in advanced lung cancer and promising results for novel therapies targeting PSMA, DKK1, and FGFR3 in various aggressive cancers. These breakthroughs hold promise for improved treatment outcomes and quality of life for patients with difficult-to-treat diseases.
A recent study found that patients with advanced lung and skin cancer who received a COVID-19 mRNA vaccine within 100 days of starting immunotherapy drugs lived significantly longer than those who did not get the vaccine. The observation marks a significant step toward a long-awaited universal cancer vaccine to boost tumor-fighting eff...
The phase 3 FLAURA2 study shows that adding platinum-pemetrexed to osimertinib improves overall survival in patients with newly diagnosed EGFR-mutated advanced NSCLC. Median overall survival was 47.5 months, compared to 37.6 months with osimertinib alone.
Researchers discovered craters on the surface of melanoma cells that serve as immune hubs and facilitate local tumor killing. These structures, termed CRATERs, may serve as a more accurate marker of immunotherapy's success in treating solid tumors.
UCSF researchers found a key cellular switch driving pulmonary fibrosis and developed a new therapy to block it in mice. The treatment works by preventing healthy lung cells from converting to harmful cell types, reducing scarring and improving lung function.
A comprehensive, multidisciplinary approach led to a nearly 72% lung cancer screening rate at the University of Rochester Medical Center. The program's success was attributed to collaboration among primary care and specialty teams, leveraging technology to flag eligible patients and streamline screenings.
Dana-Farber researchers present promising phase 3 trial results for breast, lung, and bladder cancers, including improved quality of life for metastatic breast cancer patients. The trials also explore new approaches to kidney cancer treatment and real-world data analysis for metastatic breast cancer.
A significant association was found between increased lung cancer incidence and higher reported exposure levels among World Trade Center (WTC) responders. Future studies will investigate specific exposures and histologic changes to clarify the role of WTC exposure on prognosis.
A new grading system for invasive squamous cell carcinoma of the lung has been proposed based on tumor budding, with tumors classified as low-grade (0-9 buds/0.785 mm²) or high-grade (≥10 buds/0.785 mm²). The system was validated in a test set and demonstrated improved prognostic accuracy and guide treatment decisions.
A new clinical trial report finds that stereotactic radiation therapy offers long-term survival outcomes comparable to surgery for patients with small, early-stage non-small cell lung cancer. The study included a larger patient population than previously published randomized studies and followed these patients for much longer.
Researchers found that SBRT and surgery had similar 10-year outcomes for patients with early-stage non-small cell lung cancer, with radiation offering quality-of-life benefits. The study also showed a higher acute complication rate caused by surgery.
A new robot-assisted bronchoscope has been shown to diagnose tiny lung tumors in hard-to-reach areas with over 84% success rate, more than three times higher than traditional methods. The technology enables accurate diagnosis in patients where conventional bronchoscopy offers no viable option.
Researchers at Graz University of Technology created a highly detailed digital twin of the A549 lung cancer cell line, paving the way for individualized cancer treatment. The model simulates calcium dynamics and electrical voltages, allowing for testing of drugs and personalized treatment strategies.
Armida Labs will use the funding to advance preclinical studies of Targefrin, a potential clinical candidate for pancreatic and other cancers. The grant aims to develop an anti-metastatic agent that targets the EphA2 protein, which drives cancer cell invasion and metastasis.
A new AI-powered deep learning model has been shown to accurately estimate the malignancy risk of lung nodules, achieving high detection rates while reducing false-positive results. The model outperformed existing probability-based tools in a retrospective study, with a relative reduction of 39.4% in false positives.
Researchers found that lung cancer cells can form functional synapses with neurons, supporting their growth and survival. Disrupting glutamate signalling led to lower tumour burden and longer survival in experimental mice, highlighting promising therapeutic targets.
A new study suggests that low-dose CT screening may be effective for detecting lung cancer in Asian women who have never smoked. The Female Asian Nonsmoker Screening Study found a lung cancer detection rate of 1.3% among the screened population.
Emphysema detected on low-dose chest CT scans in asymptomatic adults increases mortality risk over a 25-year follow-up period. The study found that emphysema severity is associated with higher COPD and cardiovascular disease mortality rates, suggesting it as a distinct disease entity linked to poorer health outcomes.
A new study at WCLC demonstrates that monitoring circulating tumor DNA can refine and personalize the use of consolidation immunotherapy in patients with limited-stage small cell lung cancer. Early ctDNA detection after induction chemotherapy identifies patients more likely to benefit from consolidation immunotherapy.
A large-scale survey by Lung Cancer Europe identified critical communication barriers affecting information access and understanding among lung cancer patients and caregivers. The study found that complex medical language was a major obstacle to shared decision-making, with only 56% of respondents feeling their opinion was considered i...
A randomized Phase II trial shows that resecting the primary thoracic tumor after EGFR TKI therapy may prolong disease control in patients with metastatic EGFR-mutated non-small cell lung cancer. The study aims to extend the benefits of EGFR TKI beyond standard monotherapy by targeting residual disease through surgery.
The PALOMA-2 study found that subcutaneous amivantamab every 4 weeks, combined with daily oral lazertinib, yields a high objective response rate in patients with previously untreated EGFR-mutated advanced non-small cell lung cancer. This dosing regimen offers fewer administration-related reactions and improved convenience for patients.
A clinical trial found that patients with mesothelioma who received combination immunotherapy drugs before surgery had successful surgeries and improved early outcomes. The study showed that tracking tumor DNA in the blood could help predict treatment benefit.
A phase 2a clinical trial investigated an experimental viral immunotherapy, CAN-2409, in patients with unresectable stage III/IV NSCLC who previously failed to respond adequately to ICI. Patients showed longer overall survival and increased cytotoxic effector T cells after treatment.
Concurrent durvalumab therapy did not improve overall survival compared to consolidation alone in unresectable stage 3 NSCLC patients. The trial enrolled 662 patients and showed median OS was 41.5 months in the concurrent arm versus 39.4 months in the consolidation arm.
The NADIM ADJUVANT Phase III trial suggests that adding nivolumab to adjuvant chemotherapy can reduce recurrence risk and may offer meaningful clinical benefit for patients with completely resected stage IB–IIIA non-small cell lung cancer. The three-year relapse rate was 26.7% in the experimental arm versus 40.1% in the control arm.
A UK study found that lung cancer screening can benefit older adults up to age 80 who are eligible for surgery. The research, presented at the International Association for the Study of Lung Cancer World Conference on Lung Cancer, showed comparable survival rates between younger and older patients treated with surgery.
A phase III trial found hypofractionated radiotherapy (HypoRT) with concurrent chemotherapy provides similar survival outcomes and reduced toxicity compared to the standard six-week conventional fractionated radiotherapy (ConvRT) schedule for patients with limited-stage small cell lung cancer (LS-SCLC). Patients receiving HypoRT experi...